Hudson Technologies (HDSN) Stock Price Sinks As Q3 Earnings Margins Tighten

Simply Wall St · 1d ago

Hudson Technologies just absorbed a hard hit. The stock closed at US$4.42, down 15.5% on the day, after investors reacted to fresh Q3 2026 refrigerant earnings.

The headline story is not volume; it is profitability pressure. Revenue came in at US$59.4m while net income dropped to US$2.0m, and earnings per share slipped to about US$0.05. Short term traders see a refrigerants cycle in a rough patch. Longer term holders are weighing that margin squeeze against a debt free balance sheet and a multi year regulatory tailwind that still frames the reclamation thesis.

Love the debt free balance sheet at Hudson Technologies but concerned about the earnings squeeze showing up in Q3 margins? Check out stocks with stronger profitability profiles in our list of solid balance sheet and fundamentals stocks (23 results)

Q3 2026 Earnings Summary

  • Total Revenue (Q3 2026 vs Q3 2025): US$59.4m vs. US$74.0m (down about 20%)
  • Net Income (Q3 2026 vs Q3 2025): US$2.0m vs. US$12.4m (sharp decline in profitability)
  • Basic EPS (Q3 2026 vs Q3 2025): US$0.05 per share vs. US$0.28 per share (earnings per share fell significantly)
  • Gross Margin (Q3 2026 vs Q3 2025): approximately 25% vs. approximately 32% (margin compressed, although still ahead of internal expectations)

Hudson stayed profitable while pricing slumped and volumes pivoted. Ask Charlie what Hudson Technologies’ new separation tech could change.

NasdaqCM:HDSN Trailing 12-Month Revenue & Expenses Breakdown as at Oct 2026
NasdaqCM:HDSN Trailing 12-Month Revenue & Expenses Breakdown as at Oct 2026

Hudson bullish execution story meets mixed reality

Bulls argue Hudson Technologies can turn project spending into a higher quality refrigerant platform that throws off better cash and margins.

"The main thing that has to go right is that Hudson turns its ERP rollout, service programs such as small recovery trucks, and advanced distillation projects into sustained margin and cash generation despite current freight, pricing, and SG&A pressures."

Q3 shows partial progress. Gross margin near 25% held above the low to mid 20% goal despite weaker pricing, and ERP costs already fell versus Q2. Yet net income near US$2.0m and EPS at US$0.05 signal that these projects are not yet offsetting softer HFC prices or higher overhead.

Bear case on pricing and costs gains traction

Bears worry that weak HFC prices and a heavier cost base will choke the Hudson Technologies recovery before the project pipeline matures.

"Illegal refrigerant imports in the millions of pounds together with excess inventory in distribution channels are already weighing on HFC pricing. If these pressures persist or increase, Hudson Technologies could face continued softness in refrigerant selling prices that drags on revenue and limits improvement in gross margins and earnings."

The latest quarter leans toward that concern. Average realized pricing declined about 17% and revenue fell 20% while SG&A increased US$1.9m to US$10.8m. Gross margin held at roughly 25%, yet earnings compressed sharply, and the stock is down 15.5% on the release, showing investors are treating this risk as active, not theoretical.

The price and this Narrative do not agree. → Uncover what this Narrative says Hudson Technologies is actually worth.

Hunt For Mispriced Earnings Stories

Hudson Technologies just reminded investors how quickly sentiment can change following a single earnings report. The real opportunity is identifying stocks that may be undervalued before shifting expectations alter how they are priced.

  • Company 1 - 32% below our estimate - sells high performance data centre chips and software that customers use for demanding AI workloads.
  • Company 2 - 40% below our estimate - expands a coconut based drinks platform as retailers shift shelf space toward hydration focused offerings.
  • Company 3 - 20% below our estimate - scales production of incretin therapies as healthcare systems broaden access for cardiometabolic and obesity treatments.

Three companies from the same screener. Open the full list of 30 companies trading below our fair value estimates →